Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03302234 · ClinicalTrials.gov registry record · Phase 3
Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)
A Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 568
- Enrollment target
- 20
- Study locations
NCT03302234 is a Phase 3 study of Carcinoma, Non-Small Cell Lung that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 568 participants, above the 319-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (78% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT03302234, a Phase 3 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 568 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the efficacy of pembrolizumab given in combination with either ipilimumab or placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC). The primary hypothesis of this study is that overall survival (OS) and/or progression-free survival (PFS) is prolonged in participants who receive pembrolizumab and ipilimumab compared to those who receive pembrolizumab and placebo. With Amendment 6 (effective date: 11-Dec-2020), active participants, investigator, and sponsor personnel or delegate(s) involved in the treatment administration or clinical evaluation of the participants will be unblinded. Participants will discontinue ipilimumab and placebo and participants who remain on treatment will receive open-label pembrolizumab only.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- OTHER Placebo
- BIOLOGICAL Ipilimumab
Study Locations (20)
California
- Disney Family Cancer Center ( Site 0035) - Burbank
- Pacific Cancer Care ( Site 0001) - Monterey
- John Wayne Cancer Institute ( Site 0021) - Santa Monica
Texas
- Texas Oncology-Arlington South ( Site 8006) - Arlington
- Texas Oncology-Methodist Dallas Cancer Center ( Site 8000) - Dallas
- Texas Oncology-Flower Mound ( Site 8007) - Flower Mound
Massachusetts
- Boston Medical Center ( Site 0025) - Boston
- Lahey Hospital & Medical Center ( Site 0020) - Burlington
Ohio
- The Ohio State University Wexner Medical Center ( Site 0016) - Columbus
- Mid Ohio Oncology/Hematology Inc. ( Site 0003) - Columbus
Tennessee
- University of Tennessee Erlanger Oncology & Hematology ( Site 0026) - Chattanooga
- Tennessee Cancer Specialists ( Site 0017) - Knoxville
Arizona
- Mayo Clinic Cancer Center ( Site 0007) - Phoenix
Florida
- Florida Hospital Cancer Institute ( Site 0009) - Orlando
Kentucky
- Mercy Health-Paducah Medical Oncology and Hematology ( Site 0018) - Paducah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 568 participants |
| Start Date | 2017-12-14 |
| Est. Completion | 2022-09-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03302234
The ClinicalTrials.gov registry entry for NCT03302234 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 568 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 319-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (78% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03302234 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Texas, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03302234 about?
NCT03302234 is a clinical study titled "Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)". The purpose of this study is to determine the efficacy of pembrolizumab given in combination with either ipilimumab or placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC). The primary hypothesis of this study is that overall survival (OS) and/or progres...
What is the current status of trial NCT03302234?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 568 participants. The study started on 2017-12-14. Estimated completion is 2022-09-07.
What conditions does trial NCT03302234 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT03302234?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Placebo (OTHER), Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03302234?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03302234 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Kentucky, Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
-
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RECRUITING · Phase 3
-
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.